Kinnate Biopharma Price Prediction
| KNTEDelisted Stock | USD 2.96 0.27 8.36% |
Oversold Vs Overbought
47
Oversold | Overbought |
Using Kinnate Biopharma hype-based prediction, you can estimate the value of Kinnate Biopharma from the perspective of Kinnate Biopharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Kinnate Biopharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Kinnate because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Kinnate Biopharma after-hype prediction price | USD 2.96 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as delisted stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Kinnate |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Kinnate Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Kinnate Biopharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Kinnate Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Kinnate Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Kinnate Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Kinnate Biopharma Estimiated After-Hype Price Volatility
In the context of predicting Kinnate Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Kinnate Biopharma's historical news coverage. Kinnate Biopharma's after-hype downside and upside margins for the prediction period are 2.96 and 2.96, respectively. We have considered Kinnate Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Kinnate Biopharma is very steady at this time. Analysis and calculation of next after-hype price of Kinnate Biopharma is based on 3 months time horizon.
Kinnate Biopharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Kinnate Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kinnate Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Delisted Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Kinnate Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.00 | 0.00 | 0.00 | 0.00 | 1 Events / Month | 15 Events / Month | Very soon |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
2.96 | 2.96 | 0.00 |
|
Kinnate Biopharma Hype Timeline
Kinnate Biopharma is now traded for 2.96. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Kinnate is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is now at 0.0%. %. The volatility of related hype on Kinnate Biopharma is about 0.0%, with the expected price after the next announcement by competition of 2.96. About 83.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.79. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kinnate Biopharma recorded a loss per share of 2.78. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next anticipated press release will be very soon. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.Kinnate Biopharma Related Hype Analysis
Having access to credible news sources related to Kinnate Biopharma's direct competition is more important than ever and may enhance your ability to predict Kinnate Biopharma's future price movements. Getting to know how Kinnate Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Kinnate Biopharma may potentially react to the hype associated with one of its peers.
Kinnate Biopharma Additional Predictive Modules
Most predictive techniques to examine Kinnate price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Kinnate using various technical indicators. When you analyze Kinnate charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Kinnate Biopharma Predictive Indicators
The successful prediction of Kinnate Biopharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Kinnate Biopharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Kinnate Biopharma based on analysis of Kinnate Biopharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Kinnate Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Kinnate Biopharma's related companies.
Story Coverage note for Kinnate Biopharma
The number of cover stories for Kinnate Biopharma depends on current market conditions and Kinnate Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Kinnate Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Kinnate Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Kinnate Biopharma Short Properties
Kinnate Biopharma's future price predictability will typically decrease when Kinnate Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Kinnate Biopharma often depends not only on the future outlook of the potential Kinnate Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Kinnate Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 46.6 M | |
| Cash And Short Term Investments | 154 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |